Editing Hormonal Therapy (section)

=== Metabolic (5): ===

# '''Insulin resistance'''
# '''Glucose intolerance'''
# '''Worsened glycemic control in men with a pre-existing diabetes'''
# '''Increased triglycerides, low-density lipoprotein (LDL), and total cholesterol levels'''
# '''Increased risk of metabolic syndrome'''

* '''Braga-Basaria et al. JCO 2006'''
** Population: Cross-sectional study of 58 males from 3 groups
**PCa who were undergoing ADT (for recurrent or metastatic disease) for at least 12 months before the onset of the study and were in clinical and biochemical remission (ADT group)
** Age-matched men with nonmetastatic PCa who had undergone prostatectomy and/or radiotherapy and were recently found to have an increasing prostate-specific antigen (PSA) level but had not received ADT and were eugonadal (non-ADT group)
** Age-matched healthy eugonadal men with a normal PSA (control group)
** Results
*** ADT group had significantly higher body mass index, prevelanece of metabolic syndrome, abdominal obesity, and hyperglycemia
*** ADT group had significantly lower total and free testosterone levels.
** Braga-Basaria, Milena, et al."Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy." Journal of clinical oncology 24.24 (2006): 3979-3983.